Suppr超能文献

高线粒体质量可识别出一群对化疗耐药的干细胞样癌细胞。

High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.

作者信息

Farnie Gillian, Sotgia Federica, Lisanti Michael P

机构信息

Cancer Stem Cell Research, Institute of Cancer Sciences, University of Manchester, Manchester, UK.

The Breast Cancer Now Research Unit, Institute of Cancer Sciences, University of Manchester, Manchester, UK.

出版信息

Oncotarget. 2015 Oct 13;6(31):30472-86. doi: 10.18632/oncotarget.5401.

Abstract

Chemo-resistance is a clinical barrier to more effective anti-cancer therapy. In this context, cancer stem-like cells (CSCs) are thought to be chemo-resistant, resulting in tumor recurrence and distant metastasis. Our hypothesis is that chemo-resistance in CSCs is driven, in part, by enhanced mitochondrial function. Here, we used breast cell lines and metastatic breast cancer patient samples to begin to dissect the role of mitochondrial metabolism in conferring the CSC phenotype. More specifically, we employed fluorescent staining with MitoTracker (MT) to metabolically fractionate these cell lines into mito-high and mito-low sub-populations, by flow-cytometry. Interestingly, cells with high mitochondrial mass (mito-high) were specifically enriched in a number of known CSC markers, such as aldehyde dehydrogenase (ALDH) activity, and they were ESA+/CD24-/low and formed mammospheres with higher efficiency. Large cell size is another independent characteristic of the stem cell phenotype; here, we observed a >2-fold increase in mitochondrial mass in large cells (>12-μm), relative to the smaller cell population (4-8-μm). Moreover, the mito-high cell population showed a 2.4-fold enrichment in tumor-initiating cell activity, based on limiting dilution assays in murine xenografts. Importantly, primary human breast CSCs isolated from patients with metastatic breast cancer or a patient derived xenograft (PDX) also showed the co-enrichment of ALDH activity and mitochondrial mass. Most significantly, our investigations demonstrated that mito-high cells were resistant to paclitaxel, resulting in little or no DNA damage, as measured using the comet assay. In summary, increased mitochondrial mass in a sub-population of breast cancer cells confers a stem-like phenotype and chemo-resistance. As such, our current findings have important clinical implications for over-coming drug resistance, by therapeutically targeting the mito-high CSC population.

摘要

化疗耐药是更有效抗癌治疗的临床障碍。在此背景下,癌症干细胞样细胞(CSCs)被认为具有化疗耐药性,导致肿瘤复发和远处转移。我们的假设是,CSCs中的化疗耐药部分是由线粒体功能增强驱动的。在这里,我们使用乳腺癌细胞系和转移性乳腺癌患者样本,开始剖析线粒体代谢在赋予CSC表型中的作用。更具体地说,我们通过用MitoTracker(MT)进行荧光染色,通过流式细胞术将这些细胞系代谢分离为线粒体含量高和线粒体含量低的亚群。有趣的是,线粒体质量高的细胞(mito-high)在一些已知的CSC标志物中特别富集,如醛脱氢酶(ALDH)活性,并且它们是ESA+/CD24-/低表达,并且能更高效地形成乳腺球。大细胞大小是干细胞表型的另一个独立特征;在这里,我们观察到相对于较小的细胞群体(4-8μm),大细胞(>12μm)中线粒体质量增加了2倍以上。此外,基于小鼠异种移植中的有限稀释分析,mito-high细胞群体在肿瘤起始细胞活性方面显示出2.4倍的富集。重要的是,从转移性乳腺癌患者或患者来源的异种移植(PDX)中分离出的原发性人乳腺CSCs也显示出ALDH活性和线粒体质量的共同富集。最显著的是,我们的研究表明mito-high细胞对紫杉醇耐药,使用彗星试验测量,几乎没有或没有DNA损伤。总之,乳腺癌细胞亚群中线粒体质量的增加赋予了干细胞样表型和化疗耐药性。因此,我们目前的发现对于通过治疗性靶向mito-high CSC群体来克服耐药性具有重要的临床意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d690/4741545/05da205eb5e7/oncotarget-06-30472-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验